Case Studies| July 01 2022 Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review of the Literature Richard Sotorník 0000-0003-0813-3951 ; Richard Sotorník 1Canadian Medical, Prague, Czech Republic2Third Faculty of Medicine, Charles University, Prague, Czech Republic Search for other works by this author on: This Site PubMed Google Scholar Roguel Suissa; Roguel Suissa 1Canadian Medical, Prague, Czech Republic Search for other works by this author on: This Site PubMed Google Scholar Jean-Luc Ardilouze 0000-0001-8160-0320 Jean-Luc Ardilouze 3Division of Endocrinology, University Hospital Center, Sherbrooke, Canada Search for other works by this author on: This Site PubMed Google Scholar Corresponding author: Richard Sotorník, richard.sotornik@lf3.cuni.cz Clin Diabetes 2022;40(3):373–379 https://doi.org/10.2337/cd21-0044 PubMed: 35983415 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn MailTo Cite Icon Cite Get Permissions Citation Richard Sotorník, Roguel Suissa, Jean-Luc Ardilouze; Could Overt Diabetes Be Triggered by Abuse of Selective Androgen Receptor Modulators and Growth Hormone Secretagogues? A Case Report and Review of the Literature. Clin Diabetes 1 July 2022; 40 (3): 373–379. https://doi.org/10.2337/cd21-0044 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Diabetes Search Advanced Search In October 2018, a 47-year-old male recreational bodybuilder presented to his general practitioner in Prague, Czech Republic, with polydipsia (daily fluid intake 5–6 L), polyuria, blurred vision, malaise, and weight loss of 10 kg in the past month. He did not complain of any pain or fever and was taking no regular medication except recent (3 months) use of performance-enhancing drugs (PEDs) purchased from a fitness center, including two selective androgen receptor modulators (SARMs)—RAD140 5 mg twice daily and andarine 25 mg twice daily, 5 days per week—as well as the growth hormone (GH) secretagogue (GHS)/ghrelin analog ibutamoren 25 mg daily, 5 days per week. He had no previous use of hormonal supplements. The patient reported no serious disease apart from borreliosis in 2012, seasonal pollinosis, and minor injuries related to physical activities. Three years before this visit, he underwent a routine general check-up. At that time, his weight was... You do not currently have access to this content.